Literature DB >> 9535786

Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.

G Sourvinos1, D A Spandidos.   

Abstract

Predisposition to breast cancer has been attributed to mutant BRCA1 alleles whereas no BRCA1 mutation has been described yet in sporadic breast tumours. As an initial characterization of the regulation and function of the BRCA1 gene in sporadic breast cancer, we have compared the expression of BRCA1 in thirty-five paired tumour specimens versus their corresponding adjacent normal tissue. We found two- to five-fold reduced BRCA1 expression levels in tumour specimens as compared to normal tissue. Decreased BRCA1 expression was significantly associated with loss of heterozygosity (LOH) at the BRCA1 region, as well as with negative estrogen receptor (ER) status. Our results offer an alternative explanation of how BRCA1 could play an important role in sporadic breast cancer, not via mutations in coding sequences but due to transcriptional disregulation. Decreased BRCA1 mRNA may be caused due to loss of gene copies, deletions of regulatory elements in the BRCA1 promoter or failure of transcriptional regulation by estrogen receptors. We also investigated possible relationships between BRCA1, p53, mdm-2 and p21(WAF1/CIP1) at the expression level. p53 expression was unaffected in almost all the specimens, mdm-2 was overexpressed in 18/35 specimens while 21/35 overexpressed p21. Samples exhibiting reduced BRCA1 levels simultaneously overexpressed both p21 and mdm-2, showing that BRCA1, at certain levels, even reduced up to 2.7-fold, is functional and sufficient to upregulate p21, when p53 activity is inhibited by its negative regulator, the mdm-2. On the contrary, specimens exhibiting more than 2.7-fold reduced BRCA1 levels, overexpressed p21 while mdm-2 expression was normal, allowing us to speculate that p21 transcriptional activation is due to p53 activity, in cases with dramatically decreased BRCA1 expression. Our findings provide evidence, indicating that BRCA1 might affect cell cycle regulation and loss of BRCA1 function due to decreased expression leads to cell cycle arrest, through p53 and p21 genes. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535786     DOI: 10.1006/bbrc.1998.8379

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site.

Authors:  H Ruffner; W Jiang; A G Craig; T Hunter; I M Verma
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 2.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

3.  Improvement and induction property of radiation-responsive promoter through DNA shuffling of 5'-flanking regions of the human p21 gene.

Authors:  Go Kagiya; Ryohei Ogawa; John A Cook; Rajani Choudhuri; Masanori Hatashita; Yoshikazu Tanaka; Bill G DeGraff; James B Mitchell
Journal:  J Biosci Bioeng       Date:  2010-02-04       Impact factor: 2.894

4.  Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.

Authors:  C Beger; L N Pierce; M Kruger; E G Marcusson; J M Robbins; P Welcsh; P J Welch; K Welte; M C King; J R Barber; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

5.  Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.

Authors:  Gustavo Baldassarre; Sabrina Battista; Barbara Belletti; Sanjay Thakur; Francesca Pentimalli; Francesco Trapasso; Monica Fedele; Giovanna Pierantoni; Carlo M Croce; Alfredo Fusco
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

6.  Estrogen receptor (ER) beta or p53 attenuates ERalpha-mediated transcriptional activation on the BRCA2 promoter.

Authors:  Wei Jin; Ying Chen; Gen-hong Di; Penelope Miron; Yi-feng Hou; Hui Gao; Zhi-ming Shao
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

7.  BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines.

Authors:  Natalie Tulchin; Monique Chambon; Gloria Juan; Steven Dikman; James Strauchen; Leonard Ornstein; Blase Billack; Nicholas T Woods; Alvaro N A Monteiro
Journal:  Am J Pathol       Date:  2010-01-14       Impact factor: 4.307

Review 8.  An Overview of PARP Inhibitors for the Treatment of Breast Cancer.

Authors:  Laura Cortesi; Hope S Rugo; Christian Jackisch
Journal:  Target Oncol       Date:  2021-03-12       Impact factor: 4.493

9.  Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland.

Authors:  Jolanta Pamuła; Małgorzata Krześniak; Helena Zientek; Wioletta Pekala; Marek Rusin; Ewa Grzybowska
Journal:  Hered Cancer Clin Pract       Date:  2006-01-15       Impact factor: 2.857

10.  TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.

Authors:  Pedro Kringen; Yun Wang; Vanessa Dumeaux; Jahn M Nesland; Gunnar Kristensen; Anne-Lise Borresen-Dale; Anne Dorum
Journal:  BMC Cancer       Date:  2005-10-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.